menu
    • menu
    [{"orgOrder":0,"company":"Alcon Inc","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Carbohydrate","year":"2024","type":"Acquisition","leadProduct":"HYDROXYPROPYLMETHYLCELLULOSE","moa":"||Epithelial cell adhesion molecule","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alcon Inc \/ OcuMension Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Alcon Inc \/ OcuMension Therapeutics"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Defence Research and Development Canada","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Dextrans","moa":"Plasma expander","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Defence Research and Development Canada","highestDevelopmentStatusID":"10","companyTruncated":"Sunnybrook Health Sciences Centre \/ Defence Research and Development Canada"},{"orgOrder":0,"company":"University of Birmingham","sponsor":"Tikomed | University Hospital Birmingham | Neuregenix","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Dextrans","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"University of Birmingham","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Birmingham \/ Tikomed | University Hospital Birmingham | Neuregenix","highestDevelopmentStatusID":"8","companyTruncated":"University of Birmingham \/ Tikomed | University Hospital Birmingham | Neuregenix"},{"orgOrder":0,"company":"Tikomed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Dextrans","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Tikomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tikomed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tikomed \/ Undisclosed"},{"orgOrder":0,"company":"Tikomed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dextrans","moa":"TGF-beta||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tikomed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tikomed \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Tikomed \/ Undisclosed"},{"orgOrder":0,"company":"Tikomed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dextrans","moa":"TGF-beta||Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Tikomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tikomed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tikomed \/ Undisclosed"},{"orgOrder":0,"company":"Tikomed","sponsor":"IQVIA","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"Dextrans","moa":"TGF-beta||Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Tikomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tikomed \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"Tikomed \/ IQVIA"},{"orgOrder":0,"company":"Tikomed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dextrans","moa":"TGF-beta||Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Tikomed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tikomed \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Tikomed \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Dextrans

    Menu

    Dextrans

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Alcon Inc

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Alcon Inc

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE,Dextrans,Glycerine

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Sponsor : OcuMension Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            OcuMension Acquires Alcon Eye Drops with 16.7% Equity, Strategic Partnership Begins

                            Details : OcuMension will acquire outright, Tears Natural Forte, Bion Tears, Alcaine, Fluorescite, and Cyclogyl, in the Chinese market and AR-15512, a novel topical drug candidate for dry eye.

                            Product Name : Tears Naturale Forte

                            Product Type : Carbohydrate

                            Upfront Cash : Undisclosed

                            August 12, 2024

                            Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE,Dextrans,Glycerine

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Sponsor : OcuMension Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Tikomed

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Tikomed

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LMW-Dextran Sulfate,Dextrans

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tikomed's Drug Candidate ILB® Inhibited Infection of Human Cells by Dengue, Zika and Yellow Fever Viruses in ...

                            Details : ILB® to inhibit infection of human cells by four serotypes of Dengue virus (DENV1-4), two strains of Zika virus (African and Asian) and Yellow Fever virus (vaccine strain YF17D) assessed by immunofluorescence of viral particles.

                            Product Name : ILB

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 07, 2022

                            Lead Product(s) : LMW-Dextran Sulfate,Dextrans

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Tikomed

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Tikomed

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LMW-Dextran Sulfate,Dextrans

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tikomed's Ilb® Mobilizes and Modulates Key Growth Factors That Trigger a Cascade of Neuroprotective Mechanism...

                            Details : These studies show that ILB® releases, re-distributes and modulates the bioactivity of endogeneous heparin-binding growth factors that target disease compromised nervous tissues to initiate a cascade of transcriptional, metabolic and immunological effec...

                            Product Name : ILB

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 31, 2022

                            Lead Product(s) : LMW-Dextran Sulfate,Dextrans

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Tikomed

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Tikomed

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LMW-Dextran Sulfate,Dextrans

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : IQVIA

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            TIKOMED and IQVIA Announce a Strategic Collaboration for The Development of TIKOMED's Lead Drug Platform Candi...

                            Details : The collaboration will support TikoMed's lead drug platform candidate ILB®, a broad-spectrum small molecule drug candidate with curative potential and clinical development, regulatory and commercial strategies.

                            Product Name : ILB

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            May 05, 2022

                            Lead Product(s) : LMW-Dextran Sulfate,Dextrans

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : IQVIA

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Tikomed

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Tikomed

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LMW-Dextran Sulfate,Dextrans

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tikomed's ILB® Restores Brain Energy Metabolism Following Severe Traumatic Brain Injury in the Rat

                            Details : The data from the rodent model studying severe traumatic brain injury (sTBI), showed that a single post-injury injection of ILB® has beneficial effects on the metabolic damages caused by sTBI.

                            Product Name : ILB

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 14, 2020

                            Lead Product(s) : LMW-Dextran Sulfate,Dextrans

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            University of Birmingham

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            University of Birmingham

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dextrans

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Tikomed | University Hospital Birmingham | Neuregenix

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Safety and Tolerability Study of ILB® in Patients With Amyotrophic Lateral Sclerosis (ALS)

                            Details : ILB (Dextran Sulfate) is a Other Large Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Amyotrophic Lateral Sclerosis.

                            Product Name : ILB

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 15, 2018

                            Lead Product(s) : Dextrans

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Tikomed | University Hospital Birmingham | Neuregenix

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Tikomed

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Tikomed

                            Sweden arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dextrans

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Safety, Tolerability and Efficacy of ILB in Patients With Amyotrophic Lateral Sclerosi...

                            Details : ILB (Dextran Sulfate) is a Other Large Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Amyotrophic Lateral Sclerosis.

                            Product Name : ILB

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 03, 2018

                            Lead Product(s) : Dextrans

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Sunnybrook Health Sciences Centre

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Sunnybrook Health Sciences Centre

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dextrans

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase III

                            Sponsor : Defence Research and Development Canada

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Toronto Prehospital Hypertonic Resuscitation Head Injury and Multi Organ Dysfunction Trial (TOPHR HIT)

                            Details : Dextran is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Brain Injuries, Traumatic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 17, 2012

                            Lead Product(s) : Dextrans

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase III

                            Sponsor : Defence Research and Development Canada

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth